Ketchum Fred B, Chin Nathaniel A, Erickson Claire, Lambrou Nickolas H, Basche Kristin, Gleason Carey E, Clark Lindsay
Department of Neurology School of Medicine and Public Health University of Wisconsin Madison Wisconsin USA.
Division of Geriatrics Department of Medicine University of Wisconsin School of Medicine and Public Health Madison Wisconsin USA.
Alzheimers Dement (N Y). 2023 Aug 13;9(3):e12416. doi: 10.1002/trc2.12416. eCollection 2023 Jul-Sep.
In the asymptomatic "preclinical" phase of Alzheimer's disease (AD), abnormal biomarkers indicate risk for developing cognitive impairment. Biomarker information is increasingly being disclosed to participants in research settings, and biomarker testing and results disclosure will be implemented in clinical settings in the future. Biomarker disclosure has potential psychosocial benefits and harms, impacting affected individuals and their support person(s). Limited data are available about with whom research participants share their results, information that will be necessary to develop disclosure protocols and post-disclosure resources. Additionally, existing research has been conducted in largely White cohorts, limiting applicability to future clinical populations.
We enrolled a diverse cohort of 329 adults (184 non-Hispanic White and 145 Black/African American individuals) who previously participated in AD research. After reviewing a vignette describing a hypothetical biomarker research study, participants indicated their anticipated willingness to share biomarker results with loved ones, and what reactions they anticipated from others. Using mixed-methods analysis, we identified responses related to willingness to share results.
A majority (78.7%) were willing to share their results with support persons. Many (59.6%) felt it would not be difficult to share, and most (90.6%) believed their loved ones would be supportive. The most common reasons for sharing were to prepare for possible future AD (41.0% of respondents), while the most common reason for not sharing was to avoid worrying loved ones (4.8% of respondents). A total of 7.3% of respondents related reasons regarding being unsure about sharing.
Participants' interest in sharing results supports integrating support persons into AD biomarker research, and may help maximize potential benefits for participants. Communicating with this "dyad" of research participant and support person(s) may improve involvement in research, and help prepare for implementation of clinical biomarker testing by clarifying communication preferences and the influence of support persons on psychosocial outcomes.
在阿尔茨海默病(AD)的无症状“临床前”阶段,异常生物标志物表明存在发生认知障碍的风险。生物标志物信息越来越多地在研究环境中向参与者披露,并且未来将在临床环境中实施生物标志物检测和结果披露。生物标志物披露具有潜在的心理社会效益和危害,会影响受影响的个体及其支持人员。关于研究参与者会与谁分享他们的结果的数据有限,而这些信息对于制定披露方案和披露后资源是必要的。此外,现有的研究主要在白人队列中进行,限制了其对未来临床人群的适用性。
我们招募了329名成年人组成的多样化队列(184名非西班牙裔白人个体和145名黑人/非裔美国人),他们之前参与过AD研究。在查看了一份描述假设生物标志物研究的小插曲后,参与者表示了他们预期与亲人分享生物标志物结果的意愿,以及他们预期他人会有何种反应。使用混合方法分析,我们确定了与分享结果意愿相关的反应。
大多数人(78.7%)愿意与支持人员分享他们的结果。许多人(59.6%)觉得分享并不困难,大多数人(90.6%)相信他们的亲人会给予支持。分享的最常见原因是为未来可能患AD做准备(41.0%的受访者),而不分享的最常见原因是避免让亲人担心(4.8%的受访者)。共有7.3%的受访者表示不确定是否分享。
参与者对分享结果的兴趣支持将支持人员纳入AD生物标志物研究,并可能有助于使参与者的潜在利益最大化。与研究参与者和支持人员这一“二元组”进行沟通可能会提高对研究的参与度,并通过明确沟通偏好以及支持人员对心理社会结果的影响,帮助为临床生物标志物检测的实施做好准备。